Overview

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Status:
Terminated
Trial end date:
2018-09-03
Target enrollment:
Participant gender:
Summary
The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
Phase:
Phase 3
Details
Lead Sponsor:
Scioderm, Inc.
Collaborators:
Amicus Therapeutics
Amicus Therapeutics, Inc.